Real-World Efficacy and Safety of Gemtuzumab Ozogamycin (GO) and 3 + 7 regimen in fit newly diagnosed Acute Myeloid Leukemia (AML) patients. A Retrospective multicenter study of “Rete Ematologica Pugliese” (REP)

Real-World Efficacy and Safety of Gemtuzumab Ozogamycin (GO) and 3 + 7 regimen in fit newly diagnosed Acute Myeloid Leukemia (AML) patients. A Retrospective multicenter study of “Rete Ematologica Pugliese” (REP)

Gemtuzumab Ozogamicin, a monoclonal antibody targeting CD33, linked to calicheamicin, is approved in combination with “3 + 7″ for the treatment of patients with de novo CD33 positive AML. The aim of study was to evaluate the outcome of patients receiving 3 + 7 plus GO as front-line therapy outside c...

Full description

Saved in:
Bibliographic Details
Main Authors: M. Dargenio, C. Buquicchio, D. Pastore, L. Aprile, L. Ciuffreda, G. Greco, M. Delia, V. Federico, MP. Fina, D. Seripa, R. Matera, G. Tarantini, A. Maggi, L. Melillo, V. Pavone, P. Musto, G. Specchia, N. Di Renzo
Format: Article
Language:English
Published: Elsevier 2025-01-01
Series:Leukemia Research Reports
Subjects:
Acute myeloid leukemia
Immunotherapy
Allo-HSCT
MRD
Efficacy
Online Access:http://www.sciencedirect.com/science/article/pii/S2213048925000275
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2213048925000275

Similar Items